Please login to the form below

Not currently logged in

Quintiles increases China investment and sets up regional HQ

Also partners with the Shanghai Clinical Research Centre to expand its lab testing capabilities

Quintiles is to establish regional headquarters for China in Shanghai as part of an investment plan for the country that also sees the US outsourcing company expand its local lab testing capabilities.

Quintiles is putting $14m into the new HQ facility in Shanghai that will oversee its operations in Beijing, Dalian, Hong Kong and Shanghai and eventually accommodate more than 450 employees to serve China and nearby Asian countries.

Quintiles' executive chairman Dennis Gillings said: “By broadening our investment and infrastructure here, Quintiles is ready to partner with our biopharma customers as they look to realise China's potential.”

China is already home to more pharma sales reps than the US and, with the country likely this year to become the world's third-largest pharmaceutical market, the industry is also keen to tailor its research efforts there.

Recent moves in this direction will see Lilly develop a new range of diabetes treatments specifically for Chinese patients and GlaxoSmthKline (GSK) investigate how to apply the principles of traditional Chinese medicines to its quest to discover new drugs.

Plans to tap into this interest have also seen Quintiles sign a joint venture agreement with Shanghai Clinical Research Centre (SCRC), a full-service clinical research centre, to increase its lab testing offering.

Founded under the collaborative framework of the Ministry of Science and Technology and the Shanghai Municipality in 2008, SCRC aims to help globalise drug development in China by linking pharmaceutical companies to local hospitals. The firm also hosts a bio-bank and has a translational medical research centre.

SCRC president Rongxing Gan said: “SCRC's Central Laboratory's experienced staff and modern technology will be further enhanced through Quintiles' investments. We are delighted to work closely with Quintiles to further biopharma innovation and improve human health.”

The Quintiles-SCRC collaboration follows last year's launch of Kun Tuo, Quintiles' local contract research organisation, built to help local and global biopharma companies achieve successful registration of medicines in China.

19th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...